Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | Fund Letter | Wilhelm Hertzog, Paul WhitburnRozendal Global Fund | PharmaceuticalsPharmaceuticals | Long BAYN.DE (Bayer) Bayer, a food and health science conglomerate, operates the world's largest crop science business, with leading market share in the U.S. and South America. It also operates... | BULL | View Pitch → | |
| Jan 28, 2026 | Fund Letter | PharmaceuticalsPharmaceuticals | Long BAYN.DE (Bayer) Bayer was a contributor during the quarter. Two anticipated events... | BULL | View Pitch → | ||
| Jan 27, 2026 | Fund Letter | Wilhelm Hertzog, Paul WhitburnRozendal Global Fund | PharmaceuticalsPharmaceuticals | Long BAYN.DE (Bayer) Bayer was the top contributor during the quarter. Two anticipated events... | BULL | View Pitch → | |
| Jan 8, 2026 | Fund Letter | PharmaceuticalsPharmaceuticals | Long BAYN.DE (Bayer) Bayer was a contributor during the quarter as the Germany-headquartered life sciences company's stock price recovered from depressed levels. The company continued... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.